VIDEO: Aflibercept 8 mg suppresses fluid reaccumulation in difficult DME eyes
Click Here to Manage Email Alerts
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Roger A. Goldberg, MD, MBA, discusses a post hoc analysis of the PHOTON trial investigating aflibercept 8 mg for the treatment of diabetic macular edema.
“Eight weeks after the loading phase with 8 mg aflibercept in these most difficult to treat DME eyes, we see only a 5 µm reaccumulation of fluid and change in the central retinal thickness,” he said.
In comparison, eyes treated with aflibercept 2 mg experienced a 55 µm increase in central retinal thickness, “showing that 8 mg aflibercept actually suppresses the reaccumulation of fluid in these difficult to treat DME eyes,” he said.
Collapse
Goldberg RA. Impact of baseline central retinal thickness on visual and anatomic outcomes in patients with diabetic macular edema: Post hoc analysis of the phase 2/3 PHOTON trial. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.
Read more about
Click Here to Manage Email Alerts